These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 22483309)

  • 1. Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies.
    Lima MM; Martins EF; Delattre AM; Proenca MB; Mori MA; Carabelli B; Ferraz AC
    CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):439-49. PubMed ID: 22483309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conditional deletion of Ndufs4 in dopaminergic neurons promotes Parkinson's disease-like non-motor symptoms without loss of dopamine neurons.
    Choi WS; Kim HW; Tronche F; Palmiter RD; Storm DR; Xia Z
    Sci Rep; 2017 Mar; 7():44989. PubMed ID: 28327638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms.
    Prediger RD
    J Alzheimers Dis; 2010; 20 Suppl 1():S205-20. PubMed ID: 20182024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?
    Hartmann A; Michel PP; Troadec JD; Mouatt-Prigent A; Faucheux BA; Ruberg M; Agid Y; Hirsch EC
    J Neurochem; 2001 Mar; 76(6):1785-93. PubMed ID: 11259496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
    Damier P; Hirsch EC; Agid Y; Graybiel AM
    Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventive role of PD-1 on MPTP-induced dopamine depletion in mice.
    Jung HW; Son HY; Jin GZ; Park YK
    Cell Biochem Funct; 2010 Apr; 28(3):217-23. PubMed ID: 20186864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Akt signal transduction dysfunction in Parkinson's disease.
    Timmons S; Coakley MF; Moloney AM; O' Neill C
    Neurosci Lett; 2009 Dec; 467(1):30-5. PubMed ID: 19800394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer's with parkinsonism, and Alzheimer's disease.
    Joyce JN; Smutzer G; Whitty CJ; Myers A; Bannon MJ
    Mov Disord; 1997 Nov; 12(6):885-97. PubMed ID: 9399211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electroacupuncture Promotes Recovery of Motor Function and Reduces Dopaminergic Neuron Degeneration in Rodent Models of Parkinson's Disease.
    Lin JG; Chen CJ; Yang HB; Chen YH; Hung SY
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease.
    Varastet M; Riche D; Maziere M; Hantraye P
    Neuroscience; 1994 Nov; 63(1):47-56. PubMed ID: 7898660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursolic acid attenuates oxidative stress in nigrostriatal tissue and improves neurobehavioral activity in MPTP-induced Parkinsonian mouse model.
    Rai SN; Yadav SK; Singh D; Singh SP
    J Chem Neuroanat; 2016 Jan; 71():41-9. PubMed ID: 26686287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease without nigral degeneration: a pathological correlate of scans without evidence of dopaminergic deficit (SWEDD)?
    Ling H; Kearney S; Yip HL; Silveira-Moriyama L; Revesz T; Holton JL; Strand C; Davey K; Mok KY; Polke JM; Lees AJ
    J Neurol Neurosurg Psychiatry; 2016 Jun; 87(6):633-41. PubMed ID: 26209716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifactorial sleep disturbance in Parkinson's disease.
    Albers JA; Chand P; Anch AM
    Sleep Med; 2017 Jul; 35():41-48. PubMed ID: 28619181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
    Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
    Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial lesion of the substantia nigra: relation between extent of lesion and rotational behavior.
    Carman LS; Gage FH; Shults CW
    Brain Res; 1991 Jul; 553(2):275-83. PubMed ID: 1681983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.